​

OS Therapies (OSTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

OSTX Stock Rating

OS Therapies stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

OSTX Price Target Upside V Benchmarks

TypeNameUpside
StockOS Therapies-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.40$1.40$1.40
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 2513---4
Nov, 2513---4
Oct, 2513---4
Sep, 2513---4
Aug, 2513---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 03, 2024EF HuttonBuyinitialise

Financial Forecast

EPS Forecast

$-75 $-59 $-43 $-27 $-11 $5 Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-71.77---
Avg Forecast$-0.64$-0.22$0.04$0.26
High Forecast$-0.64$-0.22$0.32$0.68
Low Forecast$-0.64$-0.22$-0.25$-0.16
Surprise %11114.06%---

Revenue Forecast

$0 $8M $16M $24M $32M $40M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast$137.00K$36.67M$25.84M$35.05M
High Forecast$137.00K$36.67M$25.84M$35.05M
Low Forecast$137.00K$36.67M$25.84M$35.05M
Surprise %----

Net Income Forecast

$-9B $-7B $-5B $-3B $-1B $500M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-8.88B---
Avg Forecast$-12.83M$-4.41M$4.42M$5.14M
High Forecast$-12.83M$-4.41M$6.42M$13.63M
Low Forecast$-12.83M$-4.41M$-5.01M$-3.21M
Surprise %69126.08%---

OSTX Forecast FAQ

Is OS Therapies stock a buy?

OS Therapies stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that OS Therapies is a favorable investment for most analysts.

What is OS Therapies's price target?

OS Therapies's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.4.

How does OS Therapies stock forecast compare to its benchmarks?

OS Therapies's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for OS Therapies over the past three months?

  • December 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is OS Therapies’s EPS forecast?

OS Therapies's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.22, marking a -99.69% decrease from the reported $-71.77 in 2024. Estimates for the following years are $0.04 in 2026, and $0.26 in 2027.

What is OS Therapies’s revenue forecast?

OS Therapies's average annual revenue forecast for its fiscal year ending in December 2025 is $36.67M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $25.84M, and $35.05M for 2027.

What is OS Therapies’s net income forecast?

OS Therapies's net income forecast for the fiscal year ending in December 2025 stands at $-4.411M, representing a -99.95% decrease from the reported $-8.883B in 2024. Projections indicate $4.42M in 2026, and $5.14M in 2027.